Canada Pension Plan Investment Board Acquires New Shares in Zimmer Biomet Holdings, Inc. $ZBH

Canada Pension Plan Investment Board bought a new position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 378,010 shares of the medical equipment provider’s stock, valued at approximately $32,543,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Brighton Jones LLC acquired a new stake in Zimmer Biomet in the 4th quarter worth approximately $204,000. Sivia Capital Partners LLC acquired a new position in Zimmer Biomet during the second quarter valued at approximately $232,000. United Bank raised its position in shares of Zimmer Biomet by 10.7% in the second quarter. United Bank now owns 11,896 shares of the medical equipment provider’s stock valued at $1,085,000 after purchasing an additional 1,153 shares during the period. Federated Hermes Inc. raised its position in shares of Zimmer Biomet by 129.2% in the second quarter. Federated Hermes Inc. now owns 2,132 shares of the medical equipment provider’s stock valued at $194,000 after purchasing an additional 1,202 shares during the period. Finally, Cerity Partners LLC lifted its stake in shares of Zimmer Biomet by 93.6% in the second quarter. Cerity Partners LLC now owns 76,785 shares of the medical equipment provider’s stock worth $7,004,000 after buying an additional 37,116 shares during the last quarter. Institutional investors and hedge funds own 88.89% of the company’s stock.

Zimmer Biomet Stock Up 1.6%

NYSE ZBH opened at $101.10 on Friday. Zimmer Biomet Holdings, Inc. has a 1-year low of $79.12 and a 1-year high of $106.88. The company has a market capitalization of $19.28 billion, a price-to-earnings ratio of 24.60, a PEG ratio of 2.70 and a beta of 0.45. The stock’s 50 day moving average is $93.88 and its two-hundred day moving average is $91.45. The company has a current ratio of 1.69, a quick ratio of 0.94 and a debt-to-equity ratio of 0.50.

Zimmer Biomet (NYSE:ZBH) last issued its earnings results on Wednesday, August 5th. The medical equipment provider reported $2.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.01 by $0.06. The business had revenue of $2.18 billion during the quarter, compared to analysts’ expectations of $2.13 billion. Zimmer Biomet had a return on equity of 13.12% and a net margin of 9.48%.Zimmer Biomet’s quarterly revenue was up 4.8% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.07 EPS. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. Equities analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.54 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts recently issued reports on ZBH shares. Sanford C. Bernstein raised their target price on shares of Zimmer Biomet from $91.00 to $93.00 and gave the company a “market perform” rating in a research note on Thursday, August 6th. Zacks Research upgraded shares of Zimmer Biomet from a “strong sell” rating to a “hold” rating in a report on Tuesday. UBS Group reaffirmed a “buy” rating and issued a $120.00 price target on shares of Zimmer Biomet in a research report on Thursday, August 6th. Weiss Ratings upgraded Zimmer Biomet from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Tuesday, August 4th. Finally, Citigroup cut their price objective on Zimmer Biomet from $95.00 to $93.00 and set a “neutral” rating for the company in a research report on Thursday, May 28th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, fourteen have assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, Zimmer Biomet presently has an average rating of “Hold” and an average target price of $104.42.

Zimmer Biomet Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.